★ | Laser Hair Growth Cap
★ Use Code: YOUTUBE ($50 OFF)
Would you sing karaoke at the Superbowl half time show if it meant you woke up the next day with a full head of hair? Let us know in the comments!
In exciting news for hair loss sufferers, the Replicel and Shiseido companies have been undergoing clinical trials on their new hair growth product, RCH-01, since 2016.
Replicel currently reports that the treatment is in stage 2 clinical trials in Tokyo.
And while we don’t know when RCH-01 will be released, you can be sure it will be hotly anticipated!
Replicel tells us that RCH-01 is a cell therapy that uses isolated dermal sheath cup (DSC) cells taken from patients to treat androgenetic alopecia.
DSC cells are found at the base of hair follicles, where they regulate hair fiber growth.
DHT, or dihydrotestosterone, is a male sex hormone that is one of the main causes of hair loss.
DHT attacks hair follicles and DSC cells, causing follicles to miniaturize and hair to thin.
It turns out that DSC cells at the back of the head are actually immune to DHT’s effects!
RCH-01 uses these immune DSC cells, isolating and growing them before reintroducing them back onto the scalp.
The hope is then that the new DHT-immune DSC cells will grow healthier and thicker hair all over the scalp.
Many people around the world want to get their hands on this hot new treatment but unfortunately, we still haven’t gotten word of when the clinical trials will finish.
And since the clinical trials haven’t been released, it’s hard to make sense of any of the possible side effects of RCH-01.
Although it’s probably safe to assume that gentle, topical treatments that encourage follicle health, like laser light therapy, might work well as a dual treatment.
So keep your patience up, this could be a game-changer!